This article is more than 5 years old. Information may no longer be current.

Pigment-epithelium-derived factor enters phase 1b trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

GAITHERSBURG, Md. — A pigment-epithelial-derived factor in development for the treatment of wet age-related macular degeneration has begun a second part of a phase 1 trial, the drug’s developer announced in a press release.

GenVec said a total of 20 patients with less advanced AMD will be enrolled at multiple centers in the United States to undergo treatment with two doses of AdPEDF. Patients will receive a single injection of the drug in the eye most severely affected by the disease, according to the release.

The phase 1b study will compare the two dosing levels to evaluate safety, tolerability and effects on vision, and to establish potential effective dosing regimens for a phase 2 trial, the company noted.